Cargando…
Adjuvant therapy for renal cell carcinoma, finally a new standard?
Localized renal cell carcinoma (RCC) has the potential to be cured with surgery alone; however, some patients have a high risk of relapse and may benefit from additional treatment. Several efforts have been made to identify effective strategies, with mostly negative results. However, recent results...
Autores principales: | Renner, Alex, Rojas, Carlos, Walton-Diaz, Annerleim, Burotto, Mauricio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9557147/ https://www.ncbi.nlm.nih.gov/pubmed/36249058 http://dx.doi.org/10.3389/fonc.2022.926661 |
Ejemplares similares
-
Neoadjuvant immunotherapy for muscle invasive urothelial bladder carcinoma: will it change current standards?
por: Renner, Alex, et al.
Publicado: (2021) -
Is Cytoreductive Nephrectomy Still a Standard of Care in Metastatic Renal Cell Carcinoma?
por: Renner, Alex, et al.
Publicado: (2019) -
MRI and Targeted Biopsy Essential Tools for an Accurate Diagnosis and Treatment Decision Making in Prostate Cancer
por: Samtani, Suraj, et al.
Publicado: (2021) -
Immune Checkpoint Inhibitor Dosing: Can We Go Lower Without Compromising Clinical Efficacy?
por: Renner, Alex, et al.
Publicado: (2019) -
MAP4K4 and cancer: ready for the main stage?
por: González-Montero, Jaime, et al.
Publicado: (2023)